It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Life-threatening bacterial infections in women after childbirth, known as puerperal sepsis, resulted in classical epidemics and remain a global health problem. While outbreaks of puerperal sepsis have been ascribed to Streptococcus pyogenes, little is known about disease mechanisms. Here, we show that the bacterial R28 protein, which is epidemiologically associated with outbreaks of puerperal sepsis, specifically targets the human receptor CEACAM1. This interaction triggers events that would favor the development of puerperal sepsis, including adhesion to cervical cells, suppression of epithelial wound repair and subversion of innate immune responses. High-resolution structural analysis showed that an R28 domain with IgI3-like fold binds to the N-terminal domain of CEACAM1. Together, these findings demonstrate that a single adhesin-receptor interaction can drive the pathogenesis of bacterial sepsis and provide molecular insights into the pathogenesis of one of the most important infectious diseases in medical history.
Infection with Streptococcus pyogenes after childbirth can have life threatening consequences. Here, Catton et al. show that the epidemiologically associated bacterial R28 protein targets the human CEACAM1 receptor to facilitate the pathogenesis of bacterial sepsis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Soden, Jo 7 ; van Strijp, Jos A. G. 8
; Singer, Bernhard B. 9 ; van Sorge, Nina M. 10
; Lindahl, Gunnar 11
; McCarthy, Alex J. 12
1 Imperial College London, Centre for Bacterial Resistance Biology, Section of Molecular Microbiology, Department of Infectious Diseases, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
2 University of Maryland, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264); Frederick National Laboratory for Cancer Research, NCI RAS Initiative, Cancer Research Technology Program, Frederick, USA (GRID:grid.418021.e) (ISNI:0000 0004 0535 8394)
3 Imperial College London, Section of Immunology of Infection, Department of Infectious Disease, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
4 Lund University, Department of Laboratory Medicine, Division of Medical Microbiology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
5 Sumy State University, Sumy, Ukraine (GRID:grid.446019.e) (ISNI:0000 0001 0570 9340); University of Duisburg-Essen, Institute of Anatomy, Medical Faculty, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445)
6 The University of Sheffield, The School of Biosciences, The Florey Institute, Sheffield, UK (GRID:grid.11835.3e) (ISNI:0000 0004 1936 9262)
7 Retrogenix, Chinley, High Peak, Chinley, UK (GRID:grid.11835.3e)
8 UMC Utrecht, Department of Medical Microbiology, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
9 University of Duisburg-Essen, Institute of Anatomy, Medical Faculty, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445)
10 UMC Utrecht, Department of Medical Microbiology, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Amsterdam UMC location University of Amsterdam, Amsterdam Institute for Infection and Immunity, Department of Medical Microbiology and Infection Prevention, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010); Amsterdam UMC, location AMC, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)
11 Lund University, Department of Laboratory Medicine, Division of Medical Microbiology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Lund University, Department of Chemistry, Division of Applied Microbiology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
12 Imperial College London, Centre for Bacterial Resistance Biology, Section of Molecular Microbiology, Department of Infectious Diseases, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); UMC Utrecht, Department of Medical Microbiology, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)




